Buying a stock on weakness can be a dangerous idea. Imagine a stock that you think may be a decent buy falls to a new 52-week low. Then a few weeks later, it hits a new low. Then another. And after a while of this tailspin, it's at a multiyear low. That's what many investors have been experiencing with Walgreens Boots Alliance (NASDAQ: WBA). Shares of the pharmacy retailer are not just near their 52-week lows but they recently even hit 27-year lows. This kind of an extreme sell-off suggests that there are serious problems under the hood that make the stock too risky of an option for many investors to consider. Let's take a look at just how risky Walgreens is, and whether it's a good contrarian buy right now, or if it is nothing more than a value trap at this point. Profitability is the biggest concern for Walgreens Walgreens has a lot of fires to put out. The business isn't generating much growth, it's facing a lot of competition from Walmart and Amazon, and it probably doesn't help that rival Rite Aid filed for bankruptcy last year. But if Walgreens improves its prospects for long-term profit growth, that can take care of what I think is its biggest issue. That's because if the company isn't generating strong margins, it won't be able to compete on price, it'll likely burn through cash, and it won't have nearly as many resources at its disposal to invest in its future growth. Technically, Walgreens is profitable. In its most recent quarter (ended May 31), it reported earnings per share (EPS) of $0.40, which was actually better than a year ago, when it incurred impairment charges and EPS was just $0.14. But net earnings of $344 million were just 0.9% of the $36.4 billion that Walgreens reported in sales. Its margins need to be a whole lot better. Otherwise, there isn't much of a buffer there for the business to be more aggressive on price or to be able to absorb an increase in costs, such as those related to its investments into healthcare and the launch of primary care clinics. Reducing its footprint could help New CEO Tim Wentworth is looking at scaling down the business by closing down locations, particularly underperforming ones. Wentworth recently said, "Seventy-five percent of our stores drive 100% of our profitability today." With a stat like that, the writing looks to be on the wall for Walgreens: It needs to cut down on the number of stores it has. Assessing which stores to keep and which to close down is a key part of the strategic review the company is undertaking. But with more than 8,000 stores, the task of shuttering potentially thousands of underperforming stores is bound to be a time-consuming process. However, in the long run, it can help Walgreens achieve a smaller footprint and incur less in administrative expenses, putting the company in a better position to achieve stronger margins. Walgreens will benefit from a much leaner and more efficient operating model. But it isn't going to be an easy turnaround by any means, and it could take a while to know whether the company is indeed on the right track. Is Walgreens a good contrarian buy or just a value trap? Walgreens stock has plummeted 76% in three years. For the shares to reverse course, it won't be easy. If it does, however, then there's certainly the case to be made that there may be a lot of upside for the healthcare stock. But even if you're a contrarian investor, this may simply be too risky of a stock to own. Walgreens has a lot going on right now, and what its business may look like in five or 10 years is anyone's guess. And with so much uncertainty, it's hard to put a value on what the company is really worth given all those unknowns and all the challenges it's facing today. While it may appear to be cheap, Walgreens definitely looks like a value trap right now. It may seem like a bargain trading at just 6 times its trailing earnings. But what good is that number if the company's earnings deteriorate further in the years ahead, particularly as it invests heavily into healthcare and launches more primary care clinics? Walgreens just isn't worth the risk. Investors are probably better off taking a wait-and-see approach with the stock. You may miss out on some potential gains if the turnaround goes well, but you could also avoid significant losses if it doesn't. Should you invest $1,000 in Walgreens Boots Alliance right now? Before you buy stock in Walgreens Boots Alliance, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Walgreens Boots Alliance wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $785,556!* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of July 8, 2024 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Walmart. The Motley Fool has a disclosure policy. Walgreens Boots Alliance Stock Hits 27-Year Lows. Has It Become a Steal of a Deal? was originally published by The Motley Fool
Walgreens Boots Alliance Stock Hits 27-Year Lows. Has It Become a Steal of a Deal?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...